We have begun analyzing our preliminary 2023 Integrated Delivery Network (IDN) survey data and have found that oncology pharmacists are once again looking forward to meeting manufacturer team members in person. Our 2022 research found providers still grappling with COVID-19 impacts and preferring virtual meetings. Now, with a better understanding of COVID and its effects, providers’ preferences are shifting toward in-person interactions, although virtual options remain in the mix.
Source: HMP Market Access Insights.
Abbreviations: HCP, health care professional.
We are now conducting our follow-up interviews, and beyond the survey findings the oncology pharmacists tell us:
Stay tuned for more insights and the publication of our 2023 IDN Oncology Trend Survey next month. Until then, please reach out with any comments or questions you may have.
Changes to Medicare, including Medicare Advantage, have important repercussions on patient access to care, oncologists’ treatment decisions, and drug manufacturers’ processes.Lee Blansett
Welcome to the April 2023 edition of our Monthly Insight Series. This month we are evaluating the desire among oncology pharmacists to return to in-person meetings.Cindy Chen
Welcome to the March 2023 edition of our Monthly Insight Series. This month we discuss how Humana terminated its employer group line of business and the implications.Chris Van Denburg